

*The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.*

Eugia US LLC (f/k/a AuroMedics Pharma LLC) has initiated a recall to the Retailer level for the product Lidocaine Hydrochloride Injection USP 2% SDV 40mg/2mL-10s from the US market due to product complaint received with the nature “The label wrap covers the barcode, making it hard to scan.”

This recall impacts only batches no: 3LC26029A and 3LC26031A. The barcode encoded on the vial label contains NDC number 55150-164-02. The same NDC information is clearly and accurately printed in human-readable format on both the vial label and the secondary carton.

Due to the label overlap, barcode scanning may be impacted. However, this issue is limited to barcode readability. The information on the label accurately describes the contents of the vial. There is no impact on the identity, strength, purity, or quality of the product.

Furthermore, there is no impact on product safety or efficacy, as all critical product information remains correctly printed and legible on the label and carton.

Lidocaine hydrochloride injection, USP is sterile, nonpyrogenic, aqueous solution that contains a local anesthetic agent and is administered parenterally by injection.

Lidocaine hydrochloride injection, USP contains lidocaine hydrochloride, which is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, monohydrochloride and has the molecular weight 270.8. Lidocaine hydrochloride (C<sub>14</sub>H<sub>22</sub>N<sub>2</sub>O • HCl). Lidocaine hydrochloride injection, USP is a sterile, nonpyrogenic, isotonic solution containing sodium chloride. The pH of the solution is adjusted to approximately 6.5 (5.0 to 7.0) with sodium hydroxide and/or hydrochloric acid.

Eugia US LLC began shipping this batch to customers nationwide on April 23, 2026.

Lidocaine Hydrochloride Injection USP 2% SDV 40mg/2mL-10s-USA Market

NDC 55150-164-02

Batch number	Expiry date
3LC26029A	Feb -2029
3LC26031A	Mar-2029